What is the role of docetaxel in the treatment of bladder cancer?

Updated: Feb 23, 2021
  • Author: Kara N Babaian, MD, FACS; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
  • Print

Intravesical docetaxel appears to be a promising agent for BCG-refractory non–muscle-invasive bladder cancer; adding maintenance treatments of docetaxel may increase the duration of recurrence-free survival. Barlow et al reported that 32 of 54 patients with BCG-refractory bladder cancer showed a complete response to 6 weekly treatments of intravesical docetaxel. [104] Median time to recurrence was 39.3 months in responders treated with maintenance docetaxel, compared with 19 months in those who did not receive maintenance therapy.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!